On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €2
Sanifit has raised €72.2 million ($80.9m) in Spain’s largest private biotech fundraiser to finance phase 3 clinical development of its rare disease drug SNF472.
Spanish biotech Sanifit is targeting calcification disorders, and says it could have a potential multi-billion dollar treatment in two kidney failure indications.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh